The first ADC was granted FDA approval in 2000 for the treatment of acute myeloid leukemia (AML); gemtuzumab ozogamicin targets CD33 and carries N-acetyl-gamma-calicheamicin as the cytotoxic payload[3]. Here, CD33 is linked to acute myeloid leukemia.